Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress
12:30pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR
Intellia Therapeutics Q4 2021 Earnings Preview
05:28pm, Wednesday, 23'rd Feb 2022 Seeking Alpha
Intellia Therapeutics (NASDAQ:NTLA) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.94 and the…
Intellia Therapeutics signs lease agreement for building manufacturing facility
01:56pm, Wednesday, 23'rd Feb 2022 Seeking Alpha
Intellia Therapeutics (NTLA) entered into a lease agreement for developing a 140K sq
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?
11:20am, Monday, 21'st Feb 2022 Zacks Investment Research
Style Box ETF report for IWO
Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022
03:06pm, Friday, 18'th Feb 2022 Benzinga
Upgrades
Roth Capital upgraded the previous rating for Denbury Inc (NYSE:DEN) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago quarter EPS of $0.05. The s
How Have Cathie Wood's Top 10 Investments Performed In The Last 6 Months?
08:14pm, Thursday, 17'th Feb 2022 Benzinga
Cathie Wood's ARK Invest ETFs are some of the hottest funds after 2020's huge stock market gains.
The ARK Innovation ETF (NYSE: ARKK) grew more than 152% in 2020, beating the Nasdaq's 43.6% return.
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q4 Earnings Expected to Decline
08:02pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022
12:30pm, Thursday, 17'th Feb 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging
Intellia (NTLA) Up on Deal With ONK for Cancer Therapies
04:50pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?
03:35pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Style Box ETF report for VTWG
Intellia (NTLA) Up on Deal With ONK for Cancer Therapies
01:09pm, Wednesday, 16'th Feb 2022
Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.
Intellia Therapeutics Pops After Forging A Cancer Deal Worth Nearly $1 Billion
06:43pm, Tuesday, 15'th Feb 2022 Investor''s Business Daily
Intellia stock surged Tuesday after the CRISPR gene-editing company forged a cancer deal with Onk Therapeutics worth nearly $1 billion.
Intellia and ONK team up for CRISPR-edited NK cell therapies for cancer (NASDAQ:NTLA)
01:42pm, Tuesday, 15'th Feb 2022 Seeking Alpha
Intellia Therapeutics (NTLA) is trading ~4% higher in the pre-market on Tuesday after announcing a licensing and collaboration agreement with ONK Therapeutics to advance…
Intellia, ONK Therapeutics to Collaborate on NK Cell Cancer Therapies >NTLA
12:49pm, Tuesday, 15'th Feb 2022 MarketWatch
By Colin Kellaher Intellia Therapeutics Inc. on Tuesday said it signed a licensing and collaboration agreement with ONK Therapeutics Ltd., a startup working…
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
12:30pm, Tuesday, 15'th Feb 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., and GALWAY, Ireland and SAN DIEGO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative ther
